Trial document

drksid header

DRKS-ID: DRKS00007109

Trial Description

start of 1:1-Block title

Title

Noninterventional study on the administration of Spasmex® 45 mg coated tablets in elderly female and male patients suffering from symptoms of urge in daily urological practice - a noninterventional study with epidemiological aspects

end of 1:1-Block title

start of 1:1-Block acronym

Trial Acronym

NIS-056

end of 1:1-Block acronym

start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url

start of 1:1-Block public summary

Brief Summary in Lay Language

In the course of this study the routine use of the registered drug Spasmex 45 mg coated tablets for the indication of overactive bladder will be documented for scientific purposes. Elderly (≥ 65 years of age) male and female patients will be enrolled in the study, who visit a urological practice due to symptoms of overactive bladder, and who receive prescription for Spasmex 45 mg coated tablets following routine diagnosis by the treating physician.
The aims of the study is to determine:
- the extent of anticholinergic drug burden with potential cognitive impairment
- the extent of morbidity
- efficacy and tolerability of the drug used
- divisibility of the coated tablet into three parts.

end of 1:1-Block public summary

start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Symptoms of an overactive bladder (OAB) (urgency, frequency and/or urge incontinence) are highly prevalent, with an increasing frequency in old age (Milsom et al. 2001). OAB affects the quality of life through to social isolation and depression (Griebling 2013). Multi-medication and additionally metabolites with anticholinergic effects may cause adverse reactions such as delirium, falls, cognitive impairment (Ancelin et al. 2006, Fox et al. 2011), and as a result lead to loss of independence (Pasina et al. 2013, Lertxundi et al. 2013), and to further deterioration of the patient's health status. Treatment with quarternary anticholinergic drugs, which are largely free of central nervous system effects, might be an approach for effective treatment of OAB without increasing the anticholinergic burden of the patients.
The described study with patients suffering from urge-symptoms will be divided into three parts:
a) an epidemiological survey
i. to determine the anticholinergic burden caused by drugs using the ACBS score and
ii. to determine and quantify the morbidity using the CIRS-G score.
b) a prospective investigation of efficacy and tolerabilty of Spasmex® 45mg coated tablets
c) a survey on the divisibility of Spasmex® 45mg coated tablets.

end of 1:1-Block scientific synopsis

start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data

start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content

start of 1:1-Block organizational data

Organizational Data

DRKS-ID: DRKS00007109
Date of Registration in DRKS: 2014/10/29
Date of Registration in Partner Registry or other Primary Registry: [---]*
Investigator Sponsored/Initiated Trial (IST/IIT): no
Ethics Approval/Approval of the Ethics Committee: Approved
(leading) Ethics Committee No.: 2014-343-f-S, Ethik-Kommission der Ärztekammer Westfalen-Lippe und der med. Fakultät der Westfälischen Wilhelms-Universität Münster

end of 1:1-Block organizational data

start of 1:n-Block secondary IDs

Secondary IDs

[---]*

end of 1:n-Block secondary IDs

start of 1:N-Block indications

Health Condition or Problem studied

MedDRA: LLT,10059617:overactive bladder
ICD10: N32.8 - Other specified disorders of bladder

end of 1:N-Block indications

start of 1:N-Block interventions

Interventions/Observational Groups

Arm 1: There is only one treatment arm. There are 3 visits per patient. The period of time between the visits corresponds to the general practice. A period of time of at least 10 days between the visits is recommended.
It will be recorded:
1. Demographic data on visit 1
2. Symptoms of overactiv bladder on visit 1, 2, and 3
3. Morbidity using the CIRS-G questionnaire on visit 1
4. Medicinal pre-treatment on visit 1
5. Comedication with anticholinergic burden using the ACBS scale on visit 1, 2 and 3
6. Additional relevant comedication on visit 1, 2 and 3
7. Documentation of the therapy regimen
8. Questioning of physician and patient regarding efficacy and tolerability on visit 2 and 3
9. Questioning of patient regarding the divisibility of the coated tablet on visit 3
10. Questioning of patient regarding adverse events on visit 2 and 3.
11. Documentation of further treatment

end of 1:N-Block interventions

start of 1:1-Block design

Characteristics

Study Type: Non-interventional
Study Type Non-Interventional: Observational study
Allocation: Single arm study
Blinding: Open (masking not used)
Who is blinded: [---]*
Control: Uncontrolled/Single arm
Purpose: Other
Assignment: Single (group)
Phase: N/A
Off-label Drug use: N/A

end of 1:1-Block design

start of 1:1-Block primary endpoint

Primary Outcome

a) to determine the anticholinergic burden caused by drugs using the total score of Anticholinergic Cognitive Burden Scale (ACBS) on visit 1, 2 and 3
b) to determine and quantify the morbidity using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G) on visit 1
c) to detemine the efficacy using the following parameters:
- number of micturitions per day (on visit 1, 2 and 3)
- intensity of urgency (on visit 1, 2 and 3)
- incontinence episodes (on visit 1, 2 and 3)
- overall assessment of efficacy by patient and by physician (on visit 2 and 3)
d) to determine the divisibility of the coated tablets using an ordinal scale (on visit 3)
e) overall assessment of tolerability by patient and by physician (on visit 2 and 3)
f) documentation of side effects (on visit 2 and 3)
A period of time of at least 10 days between the visits is recommended.

end of 1:1-Block primary endpoint

start of 1:1-Block secondary endpoint

Secondary Outcome

See Primary outcome. In this noninterventional study there are no primary or secondary endpoints. All variables will be evaluated descriptively. No hypothesis will be tested, no comparison of different populations will be done.

end of 1:1-Block secondary endpoint

start of 1:n-Block recruitment countries

Countries of Recruitment

DE: Germany

end of 1:n-Block recruitment countries

start of 1:n-Block recruitment locations

Locations of Recruitment

Doctor's Practice Leipzig
Doctor's Practice Augsburg
Doctor's Practice Berlin
Doctor's Practice Bottrop
Doctor's Practice Brackenheim
Doctor's Practice Burghausen
Doctor's Practice Darmstadt
Doctor's Practice Dillenburg
Doctor's Practice Dossenheim
Doctor's Practice Dresden
Doctor's Practice Hamburg
Doctor's Practice Heilbronn
Doctor's Practice Köln
Doctor's Practice Lengerich
Doctor's Practice Ludwigshafen am Rhein
Doctor's Practice Magdeburg
Doctor's Practice Marburg
Doctor's Practice Markkleeberg
Doctor's Practice Neunkirchen
Doctor's Practice Pößneck
Doctor's Practice Reutlingen
Doctor's Practice Schwelm
Doctor's Practice Senftenberg
Doctor's Practice Sinsheim
Doctor's Practice Ahrensburg
Doctor's Practice Alzenau
Doctor's Practice Annaberg-Buchholz
Doctor's Practice Bad Doberan
Doctor's Practice Bad Nauheim
Doctor's Practice Bad Zwischenahn
Doctor's Practice Bamberg
Doctor's Practice Bergkamen
Doctor's Practice Bielefeld
Doctor's Practice Bocholt
Doctor's Practice Bochum
Doctor's Practice Chemnitz
Doctor's Practice Dinslaken
Doctor's Practice Dortmund
Doctor's Practice Düsseldorf
Doctor's Practice Ebersberg
Doctor's Practice Eilenburg
Doctor's Practice Erfurt
Doctor's Practice Essen
Doctor's Practice Flensburg
Doctor's Practice Gelsenkirchen
Doctor's Practice Gladbeck
Doctor's Practice Göppingen
Doctor's Practice Gotha
Doctor's Practice Gröbenzell
Doctor's Practice Groitzsch
Doctor's Practice Gummersbach
Doctor's Practice Halle Saale
Doctor's Practice Hamm
Doctor's Practice Hannover
Doctor's Practice Heinsberg
Doctor's Practice Herne
Doctor's Practice Herten
Doctor's Practice Heusweiler
Doctor's Practice Hildesheim
Doctor's Practice Holzminden
Doctor's Practice Homburg
Doctor's Practice Iserlohn
Doctor's Practice Kall
Doctor's Practice Kaltenkirchen
Doctor's Practice Krefeld
Doctor's Practice Langenfeld
Doctor's Practice Lemgo
Doctor's Practice Leutkirch
Doctor's Practice Leverkusen
Doctor's Practice Lichtenstein
Doctor's Practice Lippstadt
Doctor's Practice Ludwigsburg
Doctor's Practice Lutherstadt Eisleben
Doctor's Practice Mannheim
Doctor's Practice Mechernich
Doctor's Practice Miltenberg
Doctor's Practice Mönchengladbach
Doctor's Practice Mühlacker
Doctor's Practice Niederkassel
Doctor's Practice Nienburg
Doctor's Practice Nordhausen
Doctor's Practice Nordhorn
Doctor's Practice Nürnberg
Doctor's Practice Osnabrück
Doctor's Practice Papenburg
Doctor's Practice Potsdam
Doctor's Practice Prien
Doctor's Practice Rastatt
Doctor's Practice Regensburg
Doctor's Practice Rendsburg
Doctor's Practice Saarbrücken
Doctor's Practice Schwabach
Doctor's Practice Seesen
Doctor's Practice Stockach
Doctor's Practice Stralsund
Doctor's Practice Stuttgart
Doctor's Practice Tettnang
Doctor's Practice Tirschenreuth
Doctor's Practice Trier
Doctor's Practice Troisdorf
Doctor's Practice Velbert
Doctor's Practice Völklingen
Doctor's Practice Warstein
Doctor's Practice Wedel
Doctor's Practice Wesel
Doctor's Practice Witten
Doctor's Practice Zwickau
Doctor's Practice Baesweiler
Doctor's Practice Bautzen
Doctor's Practice Bogen
Doctor's Practice Brake
Doctor's Practice Bremen
Doctor's Practice Delmenhorst
Doctor's Practice Ergolding
Doctor's Practice Hemer
Doctor's Practice Kerpen-Sindorf
Doctor's Practice Rüsselsheim
Doctor's Practice Sömmerda
Doctor's Practice Wilhelmshaven

end of 1:n-Block recruitment locations

start of 1:1-Block recruitment

Recruitment

Planned/Actual: Actual
(Anticipated or Actual) Date of First Enrollment: 2014/11/03
Target Sample Size: 1250
Monocenter/Multicenter trial: Multicenter trial
National/International: National

end of 1:1-Block recruitment

start of 1:1-Block inclusion criteria

Inclusion Criteria

Gender: Both, male and female
Minimum Age: 65 Years
Maximum Age: no maximum age

end of 1:1-Block inclusion criteria

start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

at least 65 years of age; symptoms of overactive bladder; prescription of Spasmex 45mg coated tablets

end of 1:1-Block inclusion criteria add

start of 1:1-Block exclusion criteria

Exclusion Criteria

younger than 65 years of age

end of 1:1-Block exclusion criteria

start of 1:n-Block addresses

Addresses

Primary Sponsor
start of 1:1-Block address primary-sponsor
- Dr. R. Pfleger GmbH
- 96045 Bamberg
- Germany
end of 1:1-Block address primary-sponsor

start of 1:1-Block address contact primary-sponsor
- Telephone: 0951/6043-0
- Fax: 0951/6043-29
- E-mail: [---]*
- URL: http://www.dr-pfleger.de
end of 1:1-Block address contact primary-sponsor
Collaborator, Other Address
start of 1:1-Block address other
- Ev. Krankenhaus Witter gGmbHUrologische Klinik
- Mr. Priv.-Doz. Dr. med. Andreas Wiedemann
- Pferdebachstr. 27
- 58455 Witten
- Germany
end of 1:1-Block address other

start of 1:1-Block address contact other
- Telephone: 02302/175-2521
- Fax: [---]*
- E-mail: awiedemann at diakonie-ruhr.de
- URL: http://www.evk-witten.de/ev_krankenhaus_witten/medizin/klinik_fuer_urologie
end of 1:1-Block address contact other
Contact for Scientific Queries
start of 1:1-Block address scientific-contact
- Dr. R. Pfleger GmbH
- Ms. Dr. rer. nat. Claudia Neumeister
- Emil Kemmer Str. 33
- 96103 Hallstadt
- Germany
end of 1:1-Block address scientific-contact

start of 1:1-Block address contact scientific-contact
- Telephone: 0951/6043-0
- Fax: 0951/6043-29
- E-mail: claudia.neumeister at dr-pfleger.de
- URL: http://www.dr-pfleger.de
end of 1:1-Block address contact scientific-contact
Contact for Public Queries
start of 1:1-Block address public-contact
- Dr. R. Pfleger GmbH
- Ms. Dr. rer. nat. Claudia Neumeister
- Emil Kemmer Str. 33
- 96103 Hallstadt
- Germany
end of 1:1-Block address public-contact

start of 1:1-Block address contact public-contact
- Telephone: 0951/6043-0
- Fax: 0951/6043-29
- E-mail: nis-056 at dr-pfleger.de
- URL: http://www.dr-pfleger.de
end of 1:1-Block address contact public-contact

end of 1:n-Block addresses

start of 1:n-Block material support

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)
start of 1:1-Block address materialSupport
- Dr. R. Pfleger GmbH
- 96045 Bamberg
- Germany
end of 1:1-Block address materialSupport

start of 1:1-Block address contact materialSupport
- Telephone: 0951/6043-0
- Fax: 0951/6043-29
- E-mail: [---]*
- URL: http://www.dr-pfleger.de
end of 1:1-Block address contact materialSupport

end of 1:n-Block material support

start of 1:1-Block state

Status

Recruitment Status: Recruiting complete, follow-up complete
Study Closing (LPLV): 2015/10/30

end of 1:1-Block state

start of 1:n-Block publications

Trial Publications, Results and other Documents

Paper: Ivchenko et al. 2018 Anticholinergic burden and comorbidities

end of 1:n-Block publications

Please note:
There are additional attributes available concerning this trial. To open an extended view please click here .

* This entry means the parameter is not applicable or has not been set.